Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

518
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
518
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

213
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
213
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

596
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
596

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same author

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same author

Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.

Research square·2026
Same author

Short T1 Fraction as a Marker of Myelin Content: Evidence from Postmortem MRI and Histology.

bioRxiv : the preprint server for biology·2026
Same author

Amygdala microstructural changes in subjective cognitive decline: A diffusion kurtosis and neurite orientation dispersion and density imaging study.

Journal of Alzheimer's disease : JAD·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026

相关实验视频

Updated: Jul 18, 2025

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.0K

在阿尔茨海默氏症患者的步行功能障碍.

Thomas Wisniewski1, Arjun V Masurkar2

  • 1Department of Neurology, NYU School of Medicine, New York, NY, United States; Department of Pathology, NYU School of Medicine, New York, NY, United States; Department of Psychiatry, NYU School of Medicine, New York, NY, United States; Division of Cognitive Neurology, Center for Cognitive Neurology, NYU School of Medicine, New York, NY, United States.

Handbook of clinical neurology
|August 24, 2023
PubMed
概括

步行功能障碍是阿尔茨海默病 (AD) 的早期迹象. 评估步行模式可以帮助早期发现AD并预测认知能力下降.

关键词:
阿尔茨海默病是阿尔茨海默氏症的疾病.粉样蛋白是什么 粉样蛋白是什么生物标志物 生物标志物临床综合征 临床综合征步行方式 步行方式运动障碍 运动障碍

更多相关视频

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.8K
Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

8.9K

相关实验视频

Last Updated: Jul 18, 2025

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.0K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.8K
Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion
08:19

Asymmetric Walkway: A Novel Behavioral Assay for Studying Asymmetric Locomotion

Published on: January 15, 2016

8.9K

科学领域:

  • 神经学 神经学
  • 老年病的医生 老年病的医生
  • 运动科学 运动科学

背景情况:

  • 阿尔茨海默病 (AD) 是导致痴呆的主要原因,患病率正在上升.
  • 人们越来越认识到阿尔茨海默病涉及运动症状,尤其是步行功能障碍.
  • 早期检测和疾病修饰策略对于管理AD至关重要.

研究的目的:

  • 突出阿尔茨海默病中步态异常的重要性.
  • 探索步态测量对认知和功能衰退的预测价值.
  • 建立步态评估作为一个有价值的工具在整个AD频谱.

主要方法:

  • 通过临床综合征和定量动力学评估来表型走路异常.
  • 分析横截面和纵向研究数据.
  • 与AD生物标志物 (成像,生物流体,遗传) 相对应的步态测量.

主要成果:

  • 步行功能障碍是阿尔茨海默病的常见特征,即使在临床前和前期阶段也存在.
  • 具体的步态测量可以预测个人未来的认知和功能衰退.
  • 走路的异常与所有疾病阶段的已建立的AD标志物有关.

结论:

  • 步态评估为早期AD检测提供了一种有价值的非侵入性方法.
  • 定量步态分析可以识别暗示AD的微妙运动缺陷.
  • 将步态评估纳入临床实践可以改善早期识别有风险的个体.